Firms

Palo Santo VC

Illinois · New York, New York · Chicago, Illinois

Palo Santo is a venture capital investor focused on neuroscience and mental health. It backs novel central nervous system therapeutics, next-generation psychedelic medicines and enabling technologies such as AI-driven neurotechnology. Its interdisciplinary team combines investing, biotechnology operations, clinical development and scientific advice. Founded by Daniel Goldberg, Tim Schlidt and Tony Eisenberg in 2020 and publicly launched in 2021, Palo Santo announced a USD50 million fund closing in October 2022. The current website reports 23 core investments and separately displays 27 portfolio company cards, including Beacon Biosignals, Delix Therapeutics, Reunion Neuroscience, Sensorium Therapeutics and Syndeio Biosciences. Daniel Goldberg and Edny Inui are listed as current partners; Tony Eisenberg is a venture partner.

Founded: 2020
Type: Venture capital

Funds1

Palo Santo Fund I2022-10-122022-10-12$50M
First neuroscience and psychedelic therapeutics venture fund. Publicly launched in July 2021 with USD35 million initially raised and announced closed in October 2022 at USD50 million. These announcements describe the same fund’s fundraising progression; the amounts are not additive.

Team

Andrew Wald Palo Santo VC, Investor (Signal team listing)	$1M$100K – $5M	Chicago, Illinois
Daniel Goldberg Palo Santo VC, Founder and Partner	$1M$100K – $5M	Chicago, Illinois
Kathy Goldberg Palo Santo VC, Investor	$1M$100K – $5M	Illinois
Tim Schlidt Palo Santo VC, Partner	$1M$100K – $5M	New York, New York
Tony Eisenberg Palo Santo VC, Venture Partner	$1M$100K – $5M	New York, New York

Operations and support

Adrienne JoPrincipal

Ailsa DalglieshPrincipal

Charles NicholsScientific Advisory Board Member

Edny InuiPartner

Gretchen TemelesScientific Advisory Board Member

Ingrid VergaraChief of Staff

Jason ThomasTeam Member

John D. McCorvyScientific Advisory Board Member

John GredenScientific Advisory Board Member

Julie HollandScientific Advisory Board Member

Karen ParkOperations Manager

Sean GoldyPostdoctoral Fellow

Stephen WrightScientific Advisory Board Member

Investments

$11M2026-04	Beacon Biosignals	Anthony Philippakis, Hemant Taneja, JSL Health, Palo Santo VC, Daniel Goldberg, Kicker Ventures, Samsung Next, GV
$133M2024-05-02	Reunion Neuroscience	MPM BioImpact, Novo Holdings, Mitsui & Co. Global Investment, Inc., Palo Santo VC, FemHealth Ventures, Plaisance Capital Management, Arkin Bio Capital

Funds1

Team

Operations and support

Co-investing

Investments